ViewRay inks Canadian distribution agreement
Image-guided radiation therapy developer ViewRay has signed a distribution...Read more on AuntMinnie.comRelated Reading: ViewRay secures FDA clearance for MRIdian upgrades New orders drive ViewRay revenue growth in 2018 ViewRay adds to revenue and net loss in Q3 ViewRay to launch pancreatic cancer trial ViewRay taps new CCO
Conditions: Pancreatic Cancer; Pancreatic Adenocarcinoma Interventions: Radiation: Stereotactic Body Radiation Therapy (SBRT); Drug: FOLFIRINOX Sponsor: Indiana University Withdrawn
A Wilmot Cancer Institute research team reports that combining a type of radiation therapy with immunotherapy not only cures pancreatic cancer in mice, but appears to reprogram the immune system to create an “immune memory” in the same way that a vaccine keeps the flu away.
Abstract PURPOSE: To assess the effects of different beam starting phases on dosimetric variations in the clinical target volume (CTV) and organs at risk (OARs), and to identify the relationship between plan complexity and the dosimetric impact of interplay effects in volumetric-modulated arc therapy (VMAT) plans for pancreatic cancer. METHODS: Single and double full-arc VMAT plans were generated for 11 patients. A dose of 50.4 Gy in 28 fractions was prescribed to cover 50% of the planning target volume. Patient-specific Digital Imaging and Communications in Medicine-Radiation Therapy plan files were div...
Ionizing radiation (IR) can promote migration and invasion of cancer cells, but the basis for this phenomenon has not been fully elucidated. IR increases expression of glucose-regulated protein 78kDa (GRP78) on the surface of cancer cells (CS-GRP78), and this up-regulation is associated with more aggressive behavior, radioresistance, and recurrence of cancer. Here, using various biochemical and immunological methods, including flow cytometry, cell proliferation and migration assays, Rho activation and quantitative RT-PCR assays, we investigated the mechanism by which CS-GRP78 contributes to radioresistance in pancreatic du...
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings
AbstractPurposePancreatic ductal adenocarcinoma (PDAC) is the most common and lethal subtype of pancreatic cancer, with a 5-year survival rate of
ConclusionsThe role of radiation in the management of pancreatic cancer is evolving, with many ongoing areas of active investigation. Radiation therapy is likely to become even more important as new systemic therapies are developed and there is increased focus on controlling local disease. It is important that the nuances of available data are discussed with patients and families and that care be coordinated in a multidisciplinary fashion.
Supreme Court Justice Ruth Bader Ginsburg has had another bout with cancer. The court announced that Ginsburg, 86, just completed three weeks of radiation treatment for a cancerous tumor on her pancreas. Ed O'Keefe reports.
CONCLUSION: Simplified optimization solutions implemented in the MR-Linac TPS allows to elaborate in most of cases treatment plans dosimetrically comparable with those obtained by using an advanced optimizer. A superior treatment plan quality is possible using the VMAT technique that could represent a breakthrough for the MRgART if the modern advancements will lead to shorter optimization times. PMID: 31444952 [PubMed - as supplied by publisher]
Conditions: Metastatic Pancreatic Adenocarcinoma; Refractory Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 Interventions: Biological: Nivolumab; Radiation: Radiation Therapy; Drug: TLR9 Agonist SD-101 Sponsors: University of California, Davis; National Cancer Institute (NCI); Bristol-Myers Squibb; Dynavax Technologies Corporation Not yet recruiting